Enhertu shows promising activity in met-BTC’s that are HER2-pos but also in HER2-low. Using this in HER2-low would be off label but something to consider after SOC therapy.
HER2 is a target we should be considering in BTC’s starting in the first line. The overall response rates were 80% with 55% having a CR/PR. Interestingly it seems HER2 is much more prevalent in GBC compared to cholangio’s, at least in this study.
A Phase II basket study looking at tucatinib + trastuzumab in mBTC, only 30 patients were studied as this is a small subpopulation. However, the results were compelling, with an ORR of 47%. For a 3L patient who has failed gem/cis and FOLFONI, this would be a targeted option to consider.
A South Korean study showing the superiority of 5FU/LV + liposomal irinotecan vs. 5FU/LV alone. This is an attractive option after gemcitabine + cisplatin, particularly in patients who may not tolerate oxaliplatin due to peripheral neuropathy.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
